Cellectar Biosciences, Inc.
NASDAQ: CLRB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James V. Caruso
- Employees
- 11
- Headquarters
- Florham Park, United States
- IPO year
- 2005
- Market cap
- $7.9M
- Website
- https://www.cellectar.com
Loading CLRB…
Loading profile data…Frequently asked questions about CLRB
What does Cellectar Biosciences, Inc. (CLRB) do?
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for in...
Where does CLRB trade?
Cellectar Biosciences, Inc. (CLRB) trades on the NASDAQ Capital Market.
What sector is CLRB in?
Cellectar Biosciences, Inc. (CLRB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cellectar Biosciences, Inc.?
James V. Caruso is the chief executive officer of Cellectar Biosciences, Inc. (CLRB).
Where is Cellectar Biosciences, Inc. headquartered?
Cellectar Biosciences, Inc. is headquartered in United States.
Does CLRB pay a dividend?
Cellectar Biosciences, Inc. (CLRB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CLRB go public?
Cellectar Biosciences, Inc. (CLRB) completed its initial public offering in 2005.